Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy
In an orthotropic BCa model, the FBZ@BSA/FCS NPs demonstrated pronounced tumor cell apoptosis, synergistically reduced PDL1 expression, and restructured the immune microenvironment. This culminated in an enhanced synergistic intravesical instillation approach for BCa. Consequently, our study unveils a novel RNA editor nanoagent formulation and proposes a potential synergistic therapeutic strategy. This approach significantly bolsters therapeutic efficacy, holding promise for the clinical translation of CRISPR-Cas13-based cancer perfusion treatments.
Authors
- Lida Feng (ORCID: https://orcid.org/0009-0007-4621-2948)
- Chenfan Kong
- Zeqin Yan (ORCID: https://orcid.org/0000-0001-6251-2018)
- Lisha Liu (ORCID: https://orcid.org/0000-0002-4833-9121)
- Guangzhi Li (ORCID: https://orcid.org/0009-0004-9197-7737)
- Mingkang Liang
- Yongqiang Wang (ORCID: https://orcid.org/0000-0002-7871-6610)
- Yuqing Li (ORCID: https://orcid.org/0000-0003-1706-9402)
- Chenchen Li (ORCID: https://orcid.org/0000-0002-5888-414X)
- Dashi Deng
Institutions
- Shenzhen University (CN)
- Shantou University (CN)
- Shantou University Medical College (CN)
- Shenzhen University Health Science Center (CN)
- Shenzhen Luohu People's Hospital (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1186/s13046-024-03146-0
- Citations
- 10
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 2.34